Biomea Fusion Inc (NASDAQ: BMEA)’s stock price has increased by 5.65 compared to its previous closing price of 6.19. However, the company has seen a -9.67% decrease in its stock price over the last five trading sessions. globenewswire.com reported 2024-12-06 that REDWOOD CITY, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) — Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with diabetes, obesity, and genetically defined cancers, today announced that it will host a conference call and webcast on Monday, December 9, 2024 at 4:30 pm EST to present data from COVALENT-103, the company’s Phase I trial of BMF-500, an investigational covalent FLT3 inhibitor developed using the proprietary FUSION™ System, in adult patients with relapsed or refractory acute leukemia.
Is It Worth Investing in Biomea Fusion Inc (NASDAQ: BMEA) Right Now?
BMEA has 36-month beta value of -0.55. Analysts have mixed views on the stock, with 4 analysts rating it as a “buy,” 3 as “overweight,” 2 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for BMEA is 31.63M, and currently, short sellers hold a 29.74% ratio of that float. The average trading volume of BMEA on December 06, 2024 was 761.90K shares.
BMEA’s Market Performance
BMEA stock saw a decrease of -9.67% in the past week, with a monthly decline of -26.35% and a quarterly a decrease of -4.94%. The volatility ratio for the week is 6.88%, and the volatility levels for the last 30 days are 7.53% for Biomea Fusion Inc (BMEA). The simple moving average for the last 20 days is -5.60% for BMEA stock, with a simple moving average of -31.24% for the last 200 days.
Analysts’ Opinion of BMEA
Many brokerage firms have already submitted their reports for BMEA stocks, with Edward Jones repeating the rating for BMEA by listing it as a “Buy.” The predicted price for BMEA in the upcoming period, according to Edward Jones is $128 based on the research report published on October 09, 2024 of the current year 2024.
Truist, on the other hand, stated in their research note that they expect to see BMEA reach a price target of $54. The rating they have provided for BMEA stocks is “Buy” according to the report published on September 27th, 2024.
Rodman & Renshaw gave a rating of “Buy” to BMEA, setting the target price at $18 in the report published on September 27th of the current year.
BMEA Trading at -28.09% from the 50-Day Moving Average
After a stumble in the market that brought BMEA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -68.04% of loss for the given period.
Volatility was left at 7.53%, however, over the last 30 days, the volatility rate increased by 6.88%, as shares sank -20.64% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -32.17% lower at present.
During the last 5 trading sessions, BMEA fell by -10.34%, which changed the moving average for the period of 200-days by -59.78% in comparison to the 20-day moving average, which settled at $6.93. In addition, Biomea Fusion Inc saw -54.96% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BMEA starting from Hitchcock Michael J.M., who purchase 10,000 shares at the price of $10.06 back on Sep 30 ’24. After this action, Hitchcock Michael J.M. now owns 15,000 shares of Biomea Fusion Inc, valued at $100,600 using the latest closing price.
Valle Franco, the Chief Financial Officer of Biomea Fusion Inc, purchase 12,509 shares at $4.43 during a trade that took place back on Jun 11 ’24, which means that Valle Franco is holding 42,500 shares at $55,361 based on the most recent closing price.
Stock Fundamentals for BMEA
Current profitability levels for the company are sitting at:
- -24.64 for the present operating margin
- 0.62 for the gross margin
The net margin for Biomea Fusion Inc stands at -23.45. The total capital return value is set at -1.83. Equity return is now at value -104.51, with -85.85 for asset returns.
Based on Biomea Fusion Inc (BMEA), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -41.87. The debt to equity ratio resting at 0.04. The interest coverage ratio of the stock is -154.41.
Currently, EBITDA for the company is -124.62 million with net debt to EBITDA at 0.52. When we switch over and look at the enterprise to sales, we see a ratio of 25.91. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.39.
Conclusion
To put it simply, Biomea Fusion Inc (BMEA) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
